

Apremilast (Otezla®)

Apremilast (Otezla) inhibits phosphodiesterase 4 (PDE4) specific for cyclin adenosine monophosphate (cAMP) which results in increases intracellular levels of inflammatory mediators (including TNF-alpha, and IL-23).

Resources from Manufacturer

Patient Medication Guide

[Full Prescribing Information](#)

[Otezla Co-pay Card](#)

[Amgen Patient Assistance Foundation](#)

FDA-Approved Indications and Dosing in Rheumatology

Apremilast is indicated for:

- Adult patients with active psoriatic arthritis
- Adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy
- Adult patients with oral ulcers associated with Behçet's Disease

Oral Dosing

- Psoriatic Arthritis, plaque psoriasis and Behçet's Disease: To reduce risk of gastrointestinal symptoms, titrate to recommended dosage of 30 mg twice daily according to the following schedule

| Day 1 | Day 2 | | Day 3 | | Day 4 | | Day 5 | | Day 6 & Thereafter | |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------------------|-------|
| AM | AM | PM | AM | PM | AM | PM | AM | PM | AM | PM |
| 10 mg | 10 mg | 10 mg | 10 mg | 20 mg | 20 mg | 20 mg | 20 mg | 30 mg | 30 mg | 30 mg |

Contraindications

Known hypersensitivity to apremilast or excipients

Warnings and Precautions

1. Hypersensitivity: Cases of angioedema and anaphylaxis have been reported during post marketing surveillance. Avoid use in patients with known hypersensitivity to apremilast or to any of the excipients in the formulation. If signs or symptoms of serious hypersensitivity reactions develop during treatment, discontinue and institute appropriate therapy
2. Diarrhea, Nausea, and Vomiting: Consider dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting
3. Neuropsychiatric effects: advise patients, their caregivers, and families to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes and if such changes occur to contact their healthcare provider. Carefully weigh risks and benefits of treatment
4. Weight loss: Monitor weight regularly.
5. Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended because loss of efficacy may occur

Adverse Reactions (>5%)

- Diarrhea
- Nausea
- Upper respiratory tract infections
- Headache

Medication Strength and Preparations

- Available as starter pack of 10mg, 20mg and 30mg tablets; and 30mg tablets

Medication Administration and Storage

- Tablets should be stored at room temperature between 59 to 86° F

Additional Considerations- Side effect management

- Diarrhea
 - Can consider dose reduction or interrupting therapy for severe diarrhea, nausea or vomiting. Most cases resolve within first few weeks of treatment.
 - Use caution in patients over 65 years of age and those who may be more susceptible to complications from diarrhea/vomiting.

Updated June 2023–ARP Practice Committee

DISCLAIMER: The information contained in this biologic reference guide is published by the American College of Rheumatology (“ACR”) for informational purposes only, in furtherance of its educational mission. It is not a substitute for user’s independent medical discretion or decision making, nor a replacement for the manufacturer’s complete prescribing and labeling information, as in effect at the time of use. The information contained herein reflects the conclusions of the individual companies who manufacture the products and not those of the ACR. ACR does not endorse or make any statement regarding the efficacy or safety of any of the listed companies or any of their drugs or other products. ACR specifically disclaims any and all responsibility or liability for the accuracy or completeness of the contents of this reference guide, the use of such information by anyone and/or for the performance of any of the drugs listed in this biologic reference guide (including without limitation, any adverse effects).